# Compassionate Use Study of Tenalisib (RP6530)

> **NCT03711604** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rhizen Pharmaceuticals SA** · enrollment: 17 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Tenalisib

## Key facts

- **NCT ID:** NCT03711604
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-28
- **Primary completion:** 2023-03-25
- **Final completion:** 2023-03-25
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711604, "Compassionate Use Study of Tenalisib (RP6530)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03711604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*